Rezpegaldesleukin Shows Positive Phase 2b Results for Atopic Dermatitis

Nektar Therapeutics announced the publication of positive Phase 2b REZOLVE-AD study results in The Lancet for rezpegaldesleukin, a potential treatment for moderate-to-severe atopic dermatitis. The data showed statistically significant, dose-dependent improvements in disease severity and patient-reported outcomes over 16 weeks. These findings support the drug's continued development in the ongoing Phase 3 ZENITH AD clinical program, offering hope for a new T-reg biologic treatment.